Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify predictive molecular markers of response to
continuous daily sunitinib at dose of 37.5 mg used in patients with poorly-differentiated
Advanced/Inoperable NEURO-Endocrine Tumors.
Hypothesis:
- To distinguish molecular markers based on their expression at the initial biopsy, their
detection by proteomic analysis and demonstrating that tumor or vascular cells are
straightaway sensitive to sunitinib (markers sensitivity).
- The presence of these markers at the initial biopsy predict the sensitivity to
sunitinib(Positive predictive value of markers)